# OVCH1 Antisense RNA 1 is differentially expressed between non-frail and frail old adults

**Authors:** Imad Abugessaisa, Ri-Ichiroh Manabe, Tsugumi Kawashima, Michihira Tagami, Chitose Takahashi, Yasushi Okazaki, Stefania Bandinelli, Takeya Kasukawa, Luigi Ferrucci

PMC · DOI: 10.1007/s11357-023-00961-9 · GeroScience · 2023-10-11

## TL;DR

This study finds that OVCH1 Antisense RNA 1 is expressed differently in non-frail and frail older adults, suggesting a potential role in age-related health differences.

## Contribution

The study identifies OVCH1 Antisense RNA 1 as a differentially expressed RNA in frailty and explores its potential role in age-related health decline.

## Key findings

- OVCH1 Antisense RNA 1 and other lncRNAs like XIST and TTTY14 are differentially expressed between non-frail and frail older adults.
- Glycogen Phosphorylase L (PYGL) is a top hub gene associated with frailty and non-frailty differences.
- Transcription factors FOXO3 and MYC show distinct expression patterns linked to age-related pathways in non-frail and frail individuals.

## Abstract

While some old adults stay healthy and non-frail up to late in life, others experience multimorbidity and frailty often accompanied by a pro-inflammatory state. The underlying molecular mechanisms for those differences are still obscure. Here, we used gene expression analysis to understand the molecular underpinning between non-frail and frail individuals in old age. Twenty-four adults (50% non-frail and 50% frail) from InCHIANTI study were included. Total RNA extracted from whole blood was analyzed by Cap Analysis of Gene Expression (CAGE). CAGE identified transcription start site (TSS) and active enhancer regions. We identified a set of differentially expressed (DE) TSS and enhancer between non-frail and frail and male and female participants. Several DE TSSs were annotated as lncRNA (XIST and TTTY14) and antisense RNAs (ZFX-AS1 and OVCH1 Antisense RNA 1). The promoter region chr6:366,786,54-366,787,97;+ was DE and overlapping the longevity CDKN1A gene. GWAS-LD enrichment analysis identifies overlapping LD-blocks with the DE regions with reported traits in GWAS catalog (isovolumetric relaxation time and urinary tract infection frequency). Furthermore, we used weighted gene co-expression network analysis (WGCNA) to identify changes of gene expression associated with clinical traits and identify key gene modules. We performed functional enrichment analysis of the gene modules with significant trait/module correlation. One gene module is showing a very distinct pattern in hub genes. Glycogen Phosphorylase L (PYGL) was the top ranked hub gene between non-frail and frail. We predicted transcription factor binding sites (TFBS) and motif activity. TF involved in age-related pathways (e.g., FOXO3 and MYC) shows different expression patterns between non-frail and frail participants. Expanding the study of OVCH1 Antisense RNA 1 and PYGL may help understand the mechanisms leading to loss of homeostasis that ultimately causes frailty.

The online version contains supplementary material available at 10.1007/s11357-023-00961-9.

## Linked entities

- **Genes:** XIST (X inactive specific transcript) [NCBI Gene 7503], TTTY14 (testis expressed transcript, Y-linked 14) [NCBI Gene 83869], ZFX-AS1 (ZFX antisense RNA 1) [NCBI Gene 100873922], CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026], PYGL (glycogen phosphorylase L) [NCBI Gene 5836], FOXO3 (forkhead box O3) [NCBI Gene 2309], MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609]

## Full-text entities

- **Genes:** ERG (ETS transcription factor ERG) [NCBI Gene 2078] {aka LMPHM14, erg-3, p55}, FOXO1 (forkhead box O1) [NCBI Gene 2308] {aka FKH1, FKHR, FOXO1A}, SPDEF (SAM pointed domain containing ETS transcription factor) [NCBI Gene 25803] {aka PDEF, bA375E1.3}, GPR55 (G protein-coupled receptor 55) [NCBI Gene 9290] {aka LPIR1}, OVCH1-AS1 (OVCH1 antisense RNA 1) [NCBI Gene 101055625], NFIX (nuclear factor I X) [NCBI Gene 4784] {aka CTF, MALNS, MRSHSS, NF-I/X, NF1-X, NF1A}, LAMTOR4 (late endosomal/lysosomal adaptor, MAPK and MTOR activator 4) [NCBI Gene 389541] {aka C7orf59}, SOX9 (SRY-box transcription factor 9) [NCBI Gene 6662] {aka CMD1, CMPD1, ENH13, SRA1, SRXX2, SRXY10}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, MYF5 (myogenic factor 5) [NCBI Gene 4617] {aka EORVA, bHLHc2}, TTTY14 (testis expressed transcript, Y-linked 14) [NCBI Gene 83869] {aka CYorf14, NCRNA00137, NCRNA00185, PRO2834, TTY14}, SYCE1 (synaptonemal complex central element protein 1) [NCBI Gene 93426] {aka C10orf94, CT76, POF12, SPGF15}, LOC102723370 (uncharacterized LOC102723370) [NCBI Gene 102723370], ZFX-AS1 (ZFX antisense RNA 1) [NCBI Gene 100873922], S100B (S100 calcium binding protein B) [NCBI Gene 6285] {aka NEF, S100, S100-B, S100beta}, IGLV2-14 (immunoglobulin lambda variable 2-14) [NCBI Gene 28815] {aka IGLV214, V1-4}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, CLEC2B (C-type lectin domain family 2 member B) [NCBI Gene 9976] {aka AICL, CLECSF2, HP10085, IFNRG1}, FFAR2 (free fatty acid receptor 2) [NCBI Gene 2867] {aka FFA2R, GPR43}, OVCH1 (ovochymase 1) [NCBI Gene 341350] {aka OVCH}, PYGL (glycogen phosphorylase L) [NCBI Gene 5836] {aka GSD6}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, XIST (X inactive specific transcript) [NCBI Gene 7503] {aka DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66}, DDX53 (DEAD-box helicase 53) [NCBI Gene 168400] {aka CAGE, CT26}, BHLHE23 (basic helix-loop-helix family member e23) [NCBI Gene 128408] {aka BETA4, BHLHB4, Beta3b, bA305P22.3}, CCL4L2 (C-C motif chemokine ligand 4 like 2) [NCBI Gene 9560] {aka AT744.2, CCL4L, SCYA4L, SCYQ4L2}, TTC9 (tetratricopeptide repeat domain 9) [NCBI Gene 23508] {aka TTC9A}, RORC (RAR related orphan receptor C) [NCBI Gene 6097] {aka IMD42, NR1F3, RORG, RZR-GAMMA, RZRG, TOR}, FOXO3 (forkhead box O3) [NCBI Gene 2309] {aka AF6q21, FKHRL1, FKHRL1P2, FOXO2, FOXO3A}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, C4BPA (complement component 4 binding protein alpha) [NCBI Gene 722] {aka C4BP, PRP}, NFIB (nuclear factor I B) [NCBI Gene 4781] {aka CTF, HMGIC/NFIB, MACID, NF-I/B, NF1-B, NFI-B}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, HLA-K (major histocompatibility complex, class I, K (pseudogene)) [NCBI Gene 3138] {aka HLA-70, HLA70, HLAK}, RBX1 (ring-box 1) [NCBI Gene 9978] {aka BA554C12.1, RNF75, ROC1}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, ZFX (zinc finger protein X-linked) [NCBI Gene 7543] {aka MRXS37, ZNF926}, FLI1 (Fli-1 proto-oncogene, ETS transcription factor) [NCBI Gene 2313] {aka BDPLT21, EWSR2, FLI-1, SIC-1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, S100A8 (S100 calcium binding protein A8) [NCBI Gene 6279] {aka 60B8AG, CAGA, CFAG, CGLA, CP-10, L1Ag}
- **Diseases:** Diversion colitis (MESH:D003092), disability in activities of daily living (MESH:D020773), hyperalgesia (MESH:D006930), chronic diseases (MESH:D002908), neurofibroma (MESH:D009455), frailty (MESH:D000073496), inflammation (MESH:D007249), IBD (MESH:D015212), disability (MESH:D009069), tumorigenesis (MESH:D063646), infection (MESH:D007239), autoimmune (MESH:D001327), urinary tract infection (MESH:D014552), falls (MESH:C537863), heart failure (MESH:D006333), depressive disorder (MESH:D003866), frontal fibrosing alopecia (MESH:D005355), NET (MESH:C536657), DE (MESH:D001039), loss of (MESH:D016388), Neutrophil extracellular (MESH:C535509), neurotoxicity (MESH:D020258), cancer (MESH:D009369), weakness (MESH:D018908), plantar warts (MESH:D014860), lack of energy (MESH:D001259), spermatogenic failure (MESH:C562903), esophageal cancer (MESH:D004938), venous thromboembolism (MESH:D054556), anemia (MESH:D000740), neuropathic pain (MESH:D009437), cognitive and disease (MESH:D003072), mobility disability (MESH:D014086), Alzheimer disease (MESH:D000544), weight loss (MESH:D015431), bladder transitional cell carcinoma (MESH:D002295), premature ovarian failure (MESH:D016649), major (MESH:D004830), syringoma (MESH:D018252), cardiovascular, psychiatric disorders (MESH:D001523)
- **Chemicals:** blood glucose (MESH:D001786), Imiquimod (MESH:D000077271), glycogen (MESH:D006003), creatinine (MESH:D003404), FOLLOW-UP 4 (-), triglycerides (MESH:D014280), carbohydrate (MESH:D002241), glucose (MESH:D005947)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** H169Q
- **Cell lines:** AG-1 — Rattus norvegicus (Rat), Transformed cell line (CVCL_UG77)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10828349/full.md

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10828349/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC10828349/full.md

---
Source: https://tomesphere.com/paper/PMC10828349